Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in DeltaKPQ SCN5A (long QT3) mice.

It has been suggested that both pacing and treatment with mexiletine may reduce torsade de pointes (TdP) arrhythmias in patients with long QT syndrome 3 (LQT3), but it is not fully understood how these interventions could prevent TdP. We therefore studied the effects of pacing and mexiletine in mice with a heterozygous knock-in DeltaKPQ SCN5A(Delta/+) deletion (SCN5A-Tg), a murine LQT3 model.
Three right and left ventricular monophasic action potentials (MAPs) were simultaneously recorded in Langendorff-perfused hearts of SCN5A-Tg and wild type (WT) littermates. AV block was induced, and pacing was performed at baseline and during mexiletine infusion (4 microg/ml). MAP recordings were analysed for action potential duration (APD), APD dispersion, and early afterdepolarisations (EADs) and related to spontaneous arrhythmias.
After inducing AV block, SCN5A-Tg hearts were bradycardic [SCN5A-Tg 532+/-60 vs. WT 284+/-48 ms cycle length (CL, mean+/-S.E.M., P<0.05(*))]. EADs occurred in 16/18, and polymorphic ventricular tachycardia (pVT) in 11/18 SCN5A-Tg but not in 19 WT. SCN5A-Tg had longer APD than WT hearts*. At CL of 200 ms and longer, APD dispersion was higher in SCN5A-Tg [dispersion (APD70): 12+/-3 ms vs. 5+/-2 ms at CL=200 ms*], and increased to 35+/-4 ms* directly prior to pVT episodes. Sudden rate accelerations initially increased APD dispersion due to EADs and APD alternans in SCN5A-Tg, but pacing then reduced APD dispersion. Pacing suppressed (n=9/9) and prevented (n=49/50) pVT. Mexiletine shortened APD at long CL*, and suppressed pVT (n=4/5*), but did not prevent pVT during normal rhythm.
Bradycardia, increased dispersion of APD and EADs provoke ventricular ectopy and pVT in SCN5A-Tg hearts. Ventricular pacing reduces APD dispersion, suppresses EADs and prevents pVT in SCN5A-Tg hearts. These effects provide a pathophysiological rationale for pacing in LQT3.
AuthorsLarissa Fabritz, Paulus Kirchhof, Michael R Franz, Dieter Nuyens, Tom Rossenbacker, Alexander Ottenhof, Wilhelm Haverkamp, Günter Breithardt, Edward Carmeliet, Peter Carmeliet
JournalCardiovascular research (Cardiovasc Res) Vol. 57 Issue 4 Pg. 1085-93 (Mar 15 2003) ISSN: 0008-6363 [Print] Netherlands
PMID12650887 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Arrhythmia Agents
  • NAV1.5 Voltage-Gated Sodium Channel
  • Scn5a protein, mouse
  • Sodium Channels
  • Mexiletine
  • Action Potentials (drug effects)
  • Animals
  • Anti-Arrhythmia Agents (therapeutic use)
  • Cardiac Pacing, Artificial
  • Disease Models, Animal
  • Electrocardiography
  • Gene Deletion
  • Long QT Syndrome (complications, genetics)
  • Mexiletine (therapeutic use)
  • Mice
  • Mice, Transgenic
  • NAV1.5 Voltage-Gated Sodium Channel
  • Organ Culture Techniques
  • Sodium Channels (genetics)
  • Torsades de Pointes (etiology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: